Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thor
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonar
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Reports First Quarter Financial Results and Provides Business Update
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
Savara Announces New Employment Inducement Grant
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of “Moderate Buy” from Brokerages
VR Adviser Adds Over 1 Million Savara Shares
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Announces Participation in 2026 Citizens Life Sciences Conference
Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Announces New Employment Inducement Grant
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Savara Announces New Employment Inducement Grant
Savara Inc. (SVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
Savara (NASDAQ:SVRA) & Aclaris Therapeutics (NASDAQ:ACRS) Head-To-Head Survey
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
Savara Inc. (NASDAQ:SVRA) Receives Average Recommendation of “Moderate Buy” from Analysts
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Savara: A High-Risk Opportunity
Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
SVRA DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SVRA
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Savara Inc.(SVRA) Shareholders
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
SVRA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SVRA
Shareholders that lost money on Savara Inc.(SVRA) should contact Levi & Korsinsky about pending Class Action - SVRA
Deadline Soon: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
SVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAVARA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Savara Stockholders to Contact the Firm Before November 7th
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Savara
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
Shareholders of Savara Inc. Should Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights - SVRA
SVRA DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SVRA